The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Phase II Study of Ecteinascidin-743 in Advanced Pretreated Soft Tissue Sarcoma Patients
Abstract
Purpose: A multicenter phase II study evaluating efficacy, safety, and pharmacokinetics of ecteinascidin-743 (ET-743) in pretreated advanced soft tissue sarcoma patients. Patients and Methods: Patients received ET-743 1,500 μg/m 2 (24-hour intravenous infusion) every 3 weeks (group 1, 26 patients with one to two prior single agents or one previous combination chemotherapy; group 2, 28 patients with three or more prior single agents or two or more previous combination chemotherapies). Results: Patients (30 women, 24 men) had a median age of 48 years (range, 22 to 71 years); 41% had leiomyosarcoma (eight of 22 of uterine origin), a median of two involved organs (range, one to four), and 93% had documented progressive disease at study entry. Patients received a median of three cycles (range, one to 20); 28% received six or more cycles. Fifty-two patients were assessable for response (WHO criteria): two partial responses, four minor responses, and nine with stable disease (≥ 6 months). Three patients were rendered tumor free after surgery. Median progression-free survival was 1.9 months (range, 0.69 to 17.90 months); 24% of patients were progression free at 6 months. Median survival was 12.8 months, with 30% of patients alive at 2 years. Four patients withdrew because of treatment-related toxicity. Two treatment-related deaths occurred (renal failure and febrile neutropenia, and rhabdomyolysis and decompensated cirrhosis, respectively) that were probably related to protocol eligibility violations. Reversible grade 3 to 4 AST or ALT occurred in 50% of patients and grade 3 to 4 neutropenia occurred in 61% of patients, with six episodes of febrile neutropenia. Nausea, vomiting, and asthenia were prevalent but mild and manageable. Conclusion: With a 4% overall response rate (95% CI, 0.5 to 12.8) and an 11% rate of third-party-verified tumor regression (overall response rate + minor response), ET-743 has a 24% 6-month disease progression control rate, confirming evidence of antitumoral activity and a manageable safety profile in patients experiencing disease progression with pretreated soft tissue sarcoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
(1997) · The Lancet · doi:10.1016/s0140-6736(97)08165-8 · Cited by 1,044
Frustaci, S., Gherlinzoni, F., De Paoli, A., Bonetti, M., Azzarelli, A., Comandone, A., Olmi, P., Buonadonna, A., Pignatti, G., Barbieri, E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1238 · Cited by 712
Van Glabbeke, M., van Oosterom, A. T., Oosterhuis, J. W., Mouridsen, H., Crowther, D., Somers, R., Verweij, J., Santoro, A., Buesa, J., & Tursz, T. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.150 · Cited by 608
Santoro, A., Tursz, T., Mouridsen, H., Verweij, J., Steward, W., Somers, R., Buesa, J., Casali, P., Spooner, D., & Rankin, E. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1537 · Cited by 526
Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas
Van Glabbeke, M., Verweij, J., Judson, I., & Nielsen, O. S. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00398-7 · Cited by 424
Pommier, Y., Kohlhagen, G., Bailly, C., Waring, M., Mazumder, A., & Kohn, K. W. (1996) · Biochemistry · doi:10.1021/bi960306b · Cited by 303
Patel, S. R., Vadhan-Raj, S., Papadopolous, N., Plager, C., Burgess, M. A., Hays, C., & Benjamin, R. S. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2378 · Cited by 257
Patel, S. R., Gandhi, V., Jenkins, J., Papadopolous, N., Burgess, M. A., Plager, C., Plunkett, W., & Benjamin, R. S. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.15.3483 · Cited by 247
Ecteinascidin 743: A Minor Groove Alkylator That Bends DNA toward the Major Groove
Zewail-Foote, M., & Hurley, L. H. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm990241l · Cited by 214
Le Cesne, A., Antoine, E., Spielmann, M., Le Chevalier, T., Brain, E., Toussaint, C., Janin, N., Kayitalire, L., Fontaine, F., & Genin, J. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1600 · Cited by 207
Self-citationHoff, D. D. V. (1998) · PubMed · Cited by 199
Blay, J.-Y., van Glabbeke, M., Verweij, J., van Oosterom, A. T., Le Cesne, A., Oosterhuis, J. W., Judson, I., & Nielsen, O. S. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00480-x · Cited by 184
Self-citationVerweij, J., Lee, S. M., Ruka, W., Buesa, J., Coleman, R., van Hoessel, R., Seynaeve, C., di Paola, E. D., van Glabbeke, M., Tonelli, D., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.10.2081 · Cited by 171
Delaloge, S., Yovine, A., Taamma, A., Riofrio, M., Brain, E., Raymond, E., Cottu, P., Goldwasser, F., Jimeno, J., Misset, J. L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1248 · Cited by 168
Self-citationvan Oosterom, A. T., Mouridsen, H. T., Nielsen, O. S., Dombernowsky, P., Krzemieniecki, K., Judson, I., Svancarova, L., Spooner, D., Hermans, C., Van Glabbeke, M., et al. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00491-4 · Cited by 164
Taamma, A., Misset, J. L., Riofrio, M., Guzmán, C., Brain, E. G. C., Lázaro, L. L., Rosing, H., Jimeno, J. M., & Cvitkovic, E. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1256 · Cited by 161
Self-citationIzbicka, E., Lawrence, R., Raymond, É., Eckhardt, G., Faircloth, G. T., Jimeno, J. M., Clark, G. M., & VonHoff, D. D. (1998) · Annals of Oncology · doi:10.1023/a:1008224322396 · Cited by 137
Self-citationRyan, D. P., Supko, J. G., Eder, J. P., Seiden, M. V., Demetri, G. D., Lynch, T. J., Fischman, A. J., Davis, J., Jimeno, J. A., & Clark, J. W. (2001) · PubMed · Cited by 115
Self-citationPhase II trial of gemcitabine in advanced sarcomas
Okuno, S. H., Edmonson, J. H., Mahoney, M. R., Buckner, J. C., Frytak, S., & Galanis, E. (2002) · Cancer · doi:10.1002/cncr.10602 · Cited by 96
Li, W., Takahashi, N., Jhanwar, S. C., Cordon‐Cardo, C., Elisseyeff, Y., Jimeno, J. A., Faircloth, G. T., & Bertino, J. R. (2001) · PubMed · Cited by 93
Self-citationJimeno, J. M., Faircloth, G. T., Cameron, L., Meely, K., Vega, E., Gómez, A., Sousa-Faro, J. M. F., & RINEHART, K. L. J. (1996) · Drugs of the Future · doi:10.1358/dof.1996.021.11.385487 · Cited by 87
Self-citationVillalona-Calero, M. A., Eckhardt, S. G., Weiss, G. R., Hidalgo, M. M., Beijnen, J. H., van Kesteren, C., Rosing, H., Campbell, E., Kraynak, M. A., Lázaro, L. L., et al. (2002) · PubMed · Cited by 82
Self-citationEffect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA.
Bonfanti, M., Valle, E. L., Faro, J. M. F. S., Faircloth, G. T., Caretti, G., Mantovani, R., & D’Incalci, M. (1999) · PubMed · Cited by 76
Palumbo, R., Palmeri, S., Antimi, M., Gatti, C., Raffo, P., Villani, G. M., & Toma, S. (1997) · Annals of Oncology · doi:10.1023/a:1008279426654 · Cited by 64
Puchalski, T. A., Ryan, D. P., García‐Carbonero, R., Demetri, G. D., Butkiewicz, L., Harmon, D. C., Seiden, M. V., Maki, R. G., Lázaro, L. L., Jimeno, J. M., et al. (2002) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-002-0498-3 · Cited by 63
Self-citationvan Kesteren, C., Twelves, C. J., Bowman, A., Hoekman, K., Lázaro, L. L., Jimeno, J. M., Guzmán, C., Mathôt, R. A. A., Simpson, A., Vermorken, J. B., et al. (2002) · Anti-Cancer Drugs · doi:10.1097/00001813-200204000-00007 · Cited by 45
Self-citationPhase II study of ET-743 in advanced soft-tissue sarcoma (ASTS) in adult: A STBSG-EORTC trial
Cesne, A. L., Judson, I. R., Radford, J. A., Blay, J., van Oosterom, A., Rodenhuis, S., Lorigan, P. C., Paola, E. D., Jimeno, J. M., & Verweij, J. J. (2000) · Research Explorer (The University of Manchester) · Cited by 9
Self-citationChemotherapy of colorectal cancer liver metastases
Glimelius, B. L. G. (2003) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(03)90021-8 · Cited by 3
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Drug development from marine natural products
Molinski, T. F., Dalisay, D. S., Lievens, S. L., & Saludes, J. P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2487 · Cited by 1,186
Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
von Mehren, M., Kane, J. M., Agulnik, M., Bui, M. M., Carr-Ascher, J., Choy, E., Connelly, M., Dry, S., Ganjoo, K. N., Gonzalez, R. J., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0035 · Cited by 1,182
Soft-Tissue Sarcomas in Adults
Clark, M. A., Fisher, C., Judson, I., & Thomas, J. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041866 · Cited by 907
Demetri, G. D., von Mehren, M., Jones, R. L., Hensley, M. L., Schuetze, S. M., Staddon, A., Milhem, M., Elias, A., Ganjoo, K., Tawbi, H., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.4734 · Cited by 841
Metadata
- Authors
- Yovine, A., Riofrio, M., Blay, J. Y., Brain, E., Alexandre, J., Kahatt, C., Taamma, A., Jimeno, J., Martin, C., Salhi, Y., Cvitkovic, E., & Misset, J. L.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-03-01
- Volume
- 22
- Issue
- 5
- Pages
- 890-899
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2157598836
- Cited by
- 310
- References
- 29
- FWCI
- 13.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.